Source - RNS
RNS Number : 8709I
Clinigen Group plc
07 September 2016

7 September 2016


Notification of full year results date


Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its full year results for the year ended 30 June 2016 on Wednesday, 28 September 2016.


A group analyst briefing will be held at 9:00am on Wednesday 28 September 2016 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.


Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email [email protected] to register.




Contact Details


Clinigen Group plc

Tel: +44 (0) 1283 495 010

Peter George, Group Chief Executive Officer

Shaun Chilton, Group Deputy Chief Executive Officer

Martin Abell, Group Chief Financial Officer

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Tom Ballard (Corporate Broking)

Peel Hunt LLP - Joint Broker

Tel: +44 (0) 20 7418 8900

James Steel

Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Jayne Crook / Emma Barlow

Email: [email protected]


About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.


The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.


Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.


The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).


Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.


For more information, please visit

This information is provided by RNS
The company news service from the London Stock Exchange

Related Charts

Clinigen Group (CLIN)

-8.00p (-1.08%)
delayed 18:15PM